Incentives for Global Public Health

This book examines global health problems through the lens of public and international law, focusing on access to essential medicines.

Autorentext
Thomas Pogge is Leitner Professor of Philosophy and International Affairs at Yale University, Professorial Fellow at the ANU Centre for Applied Philosophy and Public Policy (CAPPE), and Research Director at the Oslo University Centre for the Study of Mind in Nature (CSMN). Matthew Rimmer is a senior lecturer and associate director of research at the ANU College of Law, and an associate director of the Australian Centre for Intellectual Property in Agriculture. Kim Rubenstein is Professor and Director of the Centre for International and Public Law (CIPL) in the ANU College of Law, Australian National University.

Zusammenfassung
Drawing upon trade law, innovation policy, intellectual property law, health law, human rights and philosophy, this volume analyses the global health crisis and demonstrates how a combination of public and international law is essential to the development of creative solutions to the problems relating to access to essential medicines.

Inhalt
Introduction: access to essential medicines: public health and international law Thomas Pogge, Matthew Rimmer and Kim Rubenstein; Part I. International Trade: 1. TRIPS and essential medicines: must one size fit all? Making the WTO responsive to the global health crisis Rochelle Cooper Dreyfuss; 2. The TRIPS waiver as a recognition of public health concerns in the WTO Andrew Mitchell and Tania Voon; 3. Public law challenges to the regulation of pharmaceutical patents in the US Bilateral Free Trade Agreements Hitoshi Nasu; 4. Global health and development: patents and public interest Elizabeth Siew Kuan Ng; Part II. Innovation: 5. The Health Impact Fund: boosting innovation without obstructing free access Thomas Pogge; 6. The Health Impact Fund: a critique Kathleen Liddell; 7. A prize system as a partial solution to the health crisis in the developing world William W. Fisher and Talha Syed; 8. Innovation and insufficient evidence: the case for a WTO-WHO agreement on health technology safety and cost-effectiveness evaluation Thomas Faunce; Part III. Intellectual Property: 9. Opening the dam: patent pools, innovation, and access to essential medicines Dianne Nicol and Jane Nielsen; 10. Open source drug discovery: a revolutionary paradigm or a utopian model? Krishna Ravi Srinivas; 11. Accessing and benefit sharing avian influenza viruses through the World Health Organization: a CBD and TRIPS compromise thanks to Indonesia's sovereignty claim? Charles Lawson and Barbara Hocking; 12. The Lazarus effect: the (RED) campaign and creative capitalism Matthew Rimmer; Part IV. Health-Care: 13. Beyond TRIPS: the role of non-state actors and access to essential medicines Noah Benjamin Novogrodsky; 14. Securing health through rights Katharine Young; 15. The role of national laws in reconciling constitutional right to health with TRIPS obligations: an examination of the Glivec patent case in India Rajshree Chandra; 16. Tipping point: Thai compulsory licenses redefine essential medicines debate Jonathan Burton-MacLeod.

#	Onlineshop	Preis CHF	Versand CHF	Total CHF
1	Seller	0.00	0.00	0.00